Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023
2023年10月30日 - 8:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company focused on the discovery,
development and commercialization of genetic medicines to treat
diseases with high unmet medical needs, will report its third
quarter 2023 financial results on Monday, November 6, 2023,
prior to the open of U.S. markets. Subsequently, at 8:30 am
ET, the Company will host an investor conference call to discuss
the financial results and provide a business update.
Investor Conference Call
The Company will host an investor conference call
on Monday, November 6, 2023 at 8:30 am ET. To access the live
conference call, please pre-register at:
https://www.netroadshow.com/events/login?show=15609a11&confId=57029.
For those unable to listen to the live conference call, a replay
will be available for 30-days on the Investors section of the
Company’s website at www.krystalbio.com.
About Krystal Biotech, Inc.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a commercial-stage
biotechnology company focused on the discovery, development and
commercialization of genetic medicines to treat diseases with high
unmet medical needs. VYJUVEK® is the Company’s first commercial
product, the first-ever redosable gene therapy, and the only
medicine approved by the FDA for the treatment of dystrophic
epidermolysis bullosa. The Company is rapidly advancing a robust
preclinical and clinical pipeline of investigational genetic
medicines in respiratory, oncology, dermatology, ophthalmology, and
aesthetics. Krystal Biotech is headquartered in Pittsburgh,
Pennsylvania. For more information, please visit
http://www.krystalbio.com, and follow @KrystalBiotech on LinkedIn
and Twitter.
CONTACT:Investors and Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Krystal Biotech (NASDAQ:KRYS)
過去 株価チャート
から 4 2024 まで 5 2024
Krystal Biotech (NASDAQ:KRYS)
過去 株価チャート
から 5 2023 まで 5 2024